Antonio Rodriguez-Romera

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

The paper identifies chromothripsis-induced amplification of DYRK1A in blast phase MPN as a driver of aggressive disease and a potential therapeutic target.

This paper introduces comBOs, a new human bone and lympho-myeloid bone marrow organoid model that includes multiple cell types and improves upon existing models for studying haematopoietic disorders.

This study identifies a pro-inflammatory stem cell niche that drives myelofibrosis via galectin 1, offering a targetable pathway for therapy.